Adamas Pharmaceuticals (Adamas Pharmaceuticals) Debt-to-Equity : -6.21 (As of Sep. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Adamas Pharmaceuticals Debt-to-Equity?

Adamas Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $4.55 Mil. Adamas Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $129.58 Mil. Adamas Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2021 was $-21.61 Mil. Adamas Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2021 was -6.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Adamas Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

ADMS' s Debt-to-Equity Range Over the Past 10 Years
Min: -152.28 Med: 0.63 Max: 22.86
Current: -6.21

During the past 9 years, the highest Debt-to-Equity Ratio of Adamas Pharmaceuticals was 22.86. The lowest was -152.28. And the median was 0.63.

ADMS's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.29 vs ADMS: -6.21

Adamas Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Adamas Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adamas Pharmaceuticals Debt-to-Equity Chart

Adamas Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-Equity

Get a 7-Day Free Trial

1.55

1.33

-152.28

-2.73

Adamas Pharmaceuticals Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Debt-to-Equity	Get a 7-Day Free Trial															-3.95	-2.73	22.86	-33.54	-6.21

Competitive Comparison of Adamas Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Adamas Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adamas Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adamas Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Adamas Pharmaceuticals's Debt-to-Equity falls into.

Adamas Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Adamas Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.657	+	132.76)	/	-49.976
	=	-2.73

Adamas Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2021 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.554	+	129.584)	/	-21.606
	=	-6.21

Adamas Pharmaceuticals (NAS:ADMS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Adamas Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Adamas Pharmaceuticals (Adamas Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adamas Pharmaceuticals Inc (NAS:ADMS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Powell Street, Suite 1000, Emeryville, CA, USA, 94608

Website

http://www.adamaspharma.com

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

Executives

Vijay Shreedhar	officer: Chief Commercial Officer	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608
Christopher B Prentiss	officer: Chief Financial Officer	1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608
Anna Richo	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Mardi Dier	director	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
William W. Ericson	director, 10 percent owner	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
John A Macphee	director	C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608
Ivan M Lieberburg	director	11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130
Michael Bigham	director	890 WINTER STREET, WALTHAM MA 02451
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Neil F. Mcfarlane	officer: Chief Executive Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Alfred G Merriweather	officer: Chief Financial Officer
Jennifer J Rhodes	officer: CBO, GC & Compliance Officer	C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Gregory T Went	director, officer: Chief Executive Officer	C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608
Rajiv Patni	officer: Chief Medical Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301